ArticleClinical and vaccine immunology : CVI2007
Evaluation of the LIAISON chemiluminescence immunoassay for diagnosis of syphilis.
Article in Clinical and vaccine immunology : CVI, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- The Traditional or Reverse Algorithm for Diagnosis of Syphilis: Pros and Cons.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Pooled it
- Identification of typical marker proteins of Treponema pallidum in compact human bone using morphological and biochemical techniques.Scientific reports · 2025Article
- Laboratory Diagnostic Tools for Syphilis: Current Status and Future Prospects.Frontiers in cellular and infection microbiology · 2020Review
- Clinical Evaluation of Fully Automated ElecsysJournal of clinical laboratory analysis · 2016Article
- Performance Evaluation of CLIA for Treponema Pallidum Specific Antibodies Detection in Comparison with ELISA.Journal of clinical laboratory analysis · 2016Article
- Evaluation of the HISCL Anti-Treponema pallidum Assay as a Screening Test for Syphilis.Clinical and vaccine immunology : CVI · 2015Article
- Evaluation of the boson chemiluminescence immunoassay as a first-line screening test in the ECDC algorithm for syphilis serodiagnosis in a population with a high prevalence of syphilis.Journal of clinical microbiology · 2015Article
- Performance evaluation of the Elecsys syphilis assay for the detection of total antibodies to Treponema pallidum.Clinical and vaccine immunology : CVI · 2015Article
- Current trends in donor testing to detect syphilis infection.Current infectious disease reports · 2014Article
- Evaluation of the BioPlex 2200 syphilis system as a first-line method of reverse-sequence screening for syphilis diagnosis.Clinical and vaccine immunology : CVI · 2013Article
- Syphilis: using modern approaches to understand an old disease.The Journal of clinical investigation · 2011Review
- Identification of false-positive syphilis antibody results using a semiquantitative algorithm.Clinical and vaccine immunology : CVI · 2011Article
- Evaluation of a new chemiluminescence immunoassay for diagnosis of syphilis.European journal of medical research · 2010Article
- Laboratory diagnosis of syphilis with automated immunoassays.Journal of clinical laboratory analysis · 2009Article
- Evaluation of a new serological test for syphilis based on chemiluminescence assay in a tertiary care hospital.Asian journal of transfusion scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report the results of an evaluation of the LIAISON Treponema pallidum-specific assay, a one-step sandwich chemiluminescence immunoassay (CLIA), as a screening test and as a confirmatory test for the diagnosis of syphilis. The assay was compared with the CAPTIA Syphilis-G enzyme immunoassay (EIA) and with a testing algorithm that also included the rapid plasma reagin (RPR) and T. pallidum particle agglutination (PA) assays. As a screening test, the CLIA showed levels of agreement with the EIA and with the algorithm, respectively, of 94.1 and 100% for 51 samples from patients with primary or secondary syphilis, 93.2 and 98.7% for 999 samples sent to the laboratory for routine syphilis testing, 84.5 and 94.0% for 200 samples from human immunodeficiency virus-positive patients, 98.0 and 100% for 200 samples from pregnant patients, and 94.3 and 98.3% for 992 samples from apparently healthy adults. As a confirmatory test, the CLIA showed 99% agreement with the EIA for 204 RPR-positive samples. After resolution with further T. pallidum PA testing and the discarding of one sample of insufficient quantity, there was 100% agreement for the remaining 203 samples. For the total group of 2,645 samples, the overall relative sensitivity was 95.8% and the relative specificity was 99.1%. We conclude that the LIAISON CLIA demonstrated excellent sensitivity and specificity when evaluated as a confirmatory test and as a screening test for syphilis among various patient populations, including specific populations with reportedly increased rates of false-positive nontreponemal test results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.